Tyrosine kinase inhibitors
Recommendations from a Portuguese Expert Group for Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia Patients in Clinical Practice
... Tyrosine kinase inhibitors (TKIs) changed the treat- ment and survival of patients with chronic myeloid leukemia (CML) radically and are currently the cornerstone of CML treatment, improving outcomes ...
8
Protein tyrosine kinase inhibitors modify kainic acid-induced epileptiform activity and mossy fiber sprouting but do not protect against limbic cell death
... protein tyrosine kinase inhibitors used in the pres- ent study were able to modify kainate-induced epileptiform ...the inhibitors may be explained by their specificity to the wide variety of ...
8
FLT3 mutations in early T-cell precursor ALL characterize a stem cell like leukemia and imply the clinical use of tyrosine kinase inhibitors.
... Early T-cell precursor acute lymphoblastic leukemia (ETP-ALL) has been identified as high-risk subgroup of acute T- lymphoblastic leukemia (T-ALL) with a high rate of FLT3-mutations in adults. To unravel the underlying ...
10
Optimization of substituted 6-salicyl-4-anilinoquinazoline derivatives as dual EGFR/HER2 tyrosine kinase inhibitors.
... Docking study was performed to fit compound 21 into the active center of the two protein-ligand complexes of the epidermal growth factor family (PDB code: 1M17 and 3RCD, respectively). The obtained results were presented ...
11
Risk of hormone escape in a human prostate cancer model depends on therapy modalities and can be reduced by tyrosine kinase inhibitors.
... whether kinase and phosphorylation path- ways were involved in the hormone escape, as shown by others ...this kinase activates AR phosphorylation (via the MAPK pathway or AKT pathway) [18,37], which in turn ...
10
Blockade of Hedgehog Signaling Synergistically Increases Sensitivity to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer Cell Lines.
... Hh inhibitors. Combinations of Hh inhibitors and EGFR-TKIs may be an effective thera- peutic strategy for primary and secondary EGFR-TKI-resistant ...Hh inhibitors and EGFR-TKIs in EGFR-TKI- ...
16
Rev. Bras. Hematol. Hemoter. vol.30 suppl.2
... powerful tyrosine kinase inhibitors (TKIs) which are under investigation in clinical or pre-clinical studies on patients with imatinib-resistant or intolerant CML, at any stage of the ...new ...
6
Rev. Bras. Hematol. Hemoter. vol.33 número6
... BCR-ABL kinase domain is the main reason for imatinib resistance in chronic myeloid ...suitable tyrosine kinase ...aurora kinase, SRC kinase, mutation, treatment, drugs and ...New ...
6
Mecanismos de Resistência aos Inibidores da Tirosina Cinase BCR-ABL
... generation tyrosine kinase ...the inhibitors can be safely discontinued in patients who achieve long-term ...generation tyrosine kinase inhibitors has become a significant ...
7
Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT.
... intracellular kinase Lyn, and to a lesser extent, fibroblast growth factor receptor ...other tyrosine and serine/threonine ...other tyrosine kinase inhibitors; indeed, masitinib-induced ...
12
Rev. Bras. Hematol. Hemoter. vol.31 suppl.2
... powerful tyrosine kinase inhibitors (TKIs) have been developed and ...Sequential kinase inhibitor therapy is used to overcome resistance however, a future strategy might be a combination ...
4
Rev. Bras. Hematol. Hemoter. vol.39 número1
... of tyrosine kinase inhibitors to prevent relapse after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: a position ...
3
Rev. Assoc. Med. Bras. vol.59 número3 en v59n3a06
... Despite the correlation between qPCR and cytogenetic analy- sis, other prognostic factors may be associated with molecular or cytogenetic responses, affecting the outcomes during tyrosine kinase ...
13
Involvement of Src tyrosine kinase and protein kinase C in the expression of macrophage migration inhibitory factor
... H 2 O 2 -induced MIF production was completely inhibited by tyrosine kinase inhibitors genistein and PP1, as well as by protein kinase C (PKC) inhibitor GF109203X, suggesting that redox-[r] ...
6
Int. braz j urol. vol.35 número4
... Modern treatment of metastatic renal cancer involves tyrosine kinase inhibitors (TKI). This is an early report on possible lethal complications associated with this therapy in patients with brain ...
3
Rev. Bras. Hematol. Hemoter. vol.34 número5
... Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis amo[r] ...
16
Recent Updates on the Management of Medullary Thyroid Carcinoma
... two tyrosine kinase inhibitors (TKIs), vandetanib and cabozantinib, are approved for use in patients with advanced, metastatic or progressive ...
8
Rev. Bras. Hematol. Hemoter. vol.36 número1
... Extraordinary scientific progress made in the field of chronic myeloid leukemia (CML) led to the development of orally available tyrosine kinase inhibitors (TKIs), dramatically improv[r] ...
6
Insulin receptor has tyrosine kinase activity toward Shc in rat liver
... of tyrosine kinase activity is essential for most intracel- lular signaling pathways ...the tyrosine kinase capacity of their own receptors, lead to the transfer of phosphate groups of ATP to ...
6
Resistance to mTOR kinase inhibitors in lymphoma cells lacking 4EBP1.
... A cap binding assay suggested that eIF4E knockdown in VAL cells did correlate with eIF4G displacement following MLN0128 treatment; however, firm conclusions were difficult due to the low signal of eIF4E and associated ...
10